Literature DB >> 18642639

Endovascular procedures for cerebrovenous disorders.

F Y Tsai1, B Nguyen, W-C Lin, C-J Hsueh, A Yen, K Meng, V Kostanian.   

Abstract

Cerebral venous anomalies may have a variety of clinical consequences. MR or CT venogram can assist the imaging diagnosis; yet, cerebral angiogram may be required to confirm or establish the correct diagnosis. Venous anomalies predisposing venous hypertension may be categorized into three major entities such as congenital variations, outflow obstruction, and increased blood flow. The degree of clinical presentations of venous hypertension depends upon the chronicity or acuteness. Venous hypertension may lead to venous congestion with edema, hemorrhage and encephalopathy. Endovascular therapeutic procedures may be employed to relieve venous congestion either from reducing blood flow or relieving obstruction. Those endovascular treatment options include embolization, thrombolysis and angioplastic stentings.

Entities:  

Mesh:

Year:  2008        PMID: 18642639     DOI: 10.1007/978-3-211-78205-7_14

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  4 in total

1.  Venous hypertension may be a factor in aneurysmal rupture. A case report.

Authors:  K-W Lee; F Y Tsai; C-Y Cheng
Journal:  Neuroradiol J       Date:  2013-07-16

2.  Intracranial venous hemodynamics and rupture of cerebral aneurysm.

Authors:  Kwo-Whei Lee; Fong-Y Tsai; Wei-Liang Chen; Chi-Kuang Liu; Chen-Ling Kuo
Journal:  Neuroradiol J       Date:  2014-12-01

3.  Stenotic transverse sinus predisposes to poststenting hyperperfusion syndrome as evidenced by quantitative analysis of peritherapeutic cerebral circulation time.

Authors:  C-J Lin; F-C Chang; F-Y Tsai; W-Y Guo; S-C Hung; D Y-T Chen; C-H Lin; C-Y Chang
Journal:  AJNR Am J Neuroradiol       Date:  2014-01-16       Impact factor: 3.825

4.  Early imaging characteristics of 62 cases of cerebral venous sinus thrombosis.

Authors:  Hui Qu; Meilan Yang
Journal:  Exp Ther Med       Date:  2012-11-02       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.